{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:29:53Z","timestamp":1789813793265,"version":"4.0.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone marrow transplantation (BMT) is the only curative therapy for sickle cell disease (SCD). However, the morbidity and mortality related to pretransplantation myeloablative chemotherapy often outweighs the morbidity of SCD itself, thus severely limiting the number of patients eligible for transplantation. Although nonmyeloablative transplantation is expected to reduce the risk of BMT, it will likely result in mixed-chimerism rather than complete replacement with donor stem cells. Clinical application of nonmyeloablative transplantation thus requires knowledge of the effect of mixed chimerism on SCD pathophysiology. We have, therefore, created a panel of transplanted SCD mice that received transplants displaying an array of red blood cell (RBC) and white blood cell (WBC) chimerism. A significant enrichment of RBC over WBC chimerism occurred in these mice, because of the dramatic survival advantage of donor over sickle RBCs in the peripheral blood. Increasing levels of RBC chimerism provided progressive correction of hematologic and pathologic abnormalities. However, sickle bone marrow and splenic hematopoiesis was not corrected until peripheral blood sickle RBCs were fully replaced with donor RBCs. These results have important and unexpected implications for nonmyeloablative BMT for SCD. As the critical hematopoietic organs were not corrected without full RBC replacement, 100% peripheral blood RBC chimerism becomes the most important benchmark for cure after nonmyeloablative BMT. (Blood. 2003;102:4582-4593)<\/jats:p>","DOI":"10.1182\/blood-2003-03-0712","type":"journal-article","created":{"date-parts":[[2003,8,26]],"date-time":"2003-08-26T00:48:58Z","timestamp":1061858938000},"page":"4582-4593","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease"],"prefix":"10.1182","volume":"102","author":[{"given":"Leslie S.","family":"Kean","sequence":"first","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Manci","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Perry","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Balkan","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana","family":"Coley","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Holtzclaw","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Adams","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P.","family":"Larsen","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis L.","family":"Hsu","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Archer","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology\/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Centralized Pathology Unit for Sickle Cell Disease at University of South Alabama College of Medicine, Mobile; Department of Pediatrics, Division of Hematology, Ege University School of Medicine, Izmir, Turkey; and the Department of Surgery, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222212721100_REF1","unstructured":"Walters MC, Patience M, Leisenring W, et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 1996;2: 100-104."},{"key":"2020021222212721100_REF2","doi-asserted-by":"crossref","unstructured":"Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7: 665-673.","DOI":"10.1053\/bbmt.2001.v7.pm11787529"},{"key":"2020021222212721100_REF3","doi-asserted-by":"crossref","unstructured":"Eckman JR. Techniques for blood administration in sickle cell patients. Semin Hematol. 2001;38: 23-29.","DOI":"10.1016\/S0037-1963(01)90057-5"},{"key":"2020021222212721100_REF4","unstructured":"Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95: 1918-1924."},{"key":"2020021222212721100_REF5","doi-asserted-by":"crossref","unstructured":"Adams AB, Durham MM, Kean L, et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol. 2001;167: 1103-1111.","DOI":"10.4049\/jimmunol.167.2.1103"},{"key":"2020021222212721100_REF6","doi-asserted-by":"crossref","unstructured":"Kean LS, Durham MM, Adams AB, et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood. 2002;99: 1840-1849.","DOI":"10.1182\/blood.V99.5.1840"},{"key":"2020021222212721100_REF7","doi-asserted-by":"crossref","unstructured":"Kean LS, Brown LE, Nichols JW, et al. Comparison of mechanisms of anemia in mice with sickle cell disease and beta-thalassemia: peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylserine exposure. Exp Hematol. 2002;30: 394-402.","DOI":"10.1016\/S0301-472X(02)00780-4"},{"key":"2020021222212721100_REF8","doi-asserted-by":"crossref","unstructured":"de Jong K, Emerson RK, Butler J, Bastacky J, Mohandas N, Kuypers FA. Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia. Blood. 2001;98: 1577-1584.","DOI":"10.1182\/blood.V98.5.1577"},{"key":"2020021222212721100_REF9","doi-asserted-by":"crossref","unstructured":"Iannone R, Luznik L, Engstrom LW, et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood. 2001;97: 3960-3965.","DOI":"10.1182\/blood.V97.12.3960"},{"key":"2020021222212721100_REF10","doi-asserted-by":"crossref","unstructured":"Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278: 876-878.","DOI":"10.1126\/science.278.5339.876"},{"key":"2020021222212721100_REF11","doi-asserted-by":"crossref","unstructured":"Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. `Green mice' as a source of ubiquitous green cells. FEBS Lett. 1997;407: 313-319.","DOI":"10.1016\/S0014-5793(97)00313-X"},{"key":"2020021222212721100_REF12","doi-asserted-by":"crossref","unstructured":"Zhao Y, Lin Y, Zhan Y, et al. Murine hematopoietic stem cell characterization and its regulation in BM transplantation. Blood. 2000;96: 3016-3022.","DOI":"10.1182\/blood.V96.9.3016"},{"key":"2020021222212721100_REF13","doi-asserted-by":"crossref","unstructured":"Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-\/-)5b(-\/-) mice due to decreased survival of early erythroblasts. Blood. 2001;98: 3261-3273.","DOI":"10.1182\/blood.V98.12.3261"},{"key":"2020021222212721100_REF14","doi-asserted-by":"crossref","unstructured":"Kina T, Ikuta K, Takayama E, et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol. 2000;109: 280-287.","DOI":"10.1046\/j.1365-2141.2000.02037.x"},{"key":"2020021222212721100_REF15","unstructured":"Christian JA, Rebar AH, Boon GD, Low PS. Methodologic considerations for the use of canine in vivo aged biotinylated erythrocytes to study RBC senescence. Exp Hematol. 1996;24: 82-88."},{"key":"2020021222212721100_REF16","unstructured":"Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med. 1994;123: 741-748."},{"key":"2020021222212721100_","doi-asserted-by":"crossref","unstructured":"Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood. 1996;88: 1873-1880.","DOI":"10.1182\/blood.V88.5.1873.1873"},{"key":"2020021222212721100_","doi-asserted-by":"crossref","unstructured":"de Jong K, Larkin SK, Styles LA, Bookchin RM, Kuypers FA. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood. 2001;98: 860-867.","DOI":"10.1182\/blood.V98.3.860"},{"key":"2020021222212721100_","doi-asserted-by":"crossref","unstructured":"Setty BN, Kulkarni S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood. 2002;99: 1564-1571.","DOI":"10.1182\/blood.V99.5.1564"},{"key":"2020021222212721100_REF20","doi-asserted-by":"crossref","unstructured":"Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood. 2001;98: 3228-3233.","DOI":"10.1182\/blood.V98.12.3228"},{"key":"2020021222212721100_REF21","doi-asserted-by":"crossref","unstructured":"Setty BN, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood. 1996;88: 2311-2320.","DOI":"10.1182\/blood.V88.6.2311.bloodjournal8862311"},{"key":"2020021222212721100_REF22","doi-asserted-by":"crossref","unstructured":"Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol. 1996;81: 96-98.","DOI":"10.1006\/clin.1996.0163"},{"key":"2020021222212721100_REF23","doi-asserted-by":"crossref","unstructured":"Hebbel RP. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med. 2000;342: 1910-1912.","DOI":"10.1056\/NEJM200006223422512"},{"key":"2020021222212721100_REF24","doi-asserted-by":"crossref","unstructured":"Makis AC, Hatzimichael EC, Bourantas KL. The role of cytokines in sickle cell disease. Ann Hematol. 2000;79: 407-413.","DOI":"10.1007\/s002770000173"},{"key":"2020021222212721100_","doi-asserted-by":"crossref","unstructured":"Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106: 337-338.","DOI":"10.1172\/JCI10726"},{"key":"2020021222212721100_REF26","doi-asserted-by":"crossref","unstructured":"Platt OS. The acute chest syndrome of sickle cell disease. N Engl J Med. 2000;342: 1904-1907.","DOI":"10.1056\/NEJM200006223422510"},{"key":"2020021222212721100_REF27","doi-asserted-by":"crossref","unstructured":"Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000;6: 464-469.","DOI":"10.1038\/74731"},{"key":"2020021222212721100_","doi-asserted-by":"crossref","unstructured":"Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med. 1997;3: 783-787.","DOI":"10.1038\/nm0797-783"},{"key":"2020021222212721100_","doi-asserted-by":"crossref","unstructured":"Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 1998;187: 2037-2044.","DOI":"10.1084\/jem.187.12.2037"},{"key":"2020021222212721100_REF30","doi-asserted-by":"crossref","unstructured":"Durham MM, Bingaman AW, Adams AB, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol. 2000;165: 1-4.","DOI":"10.4049\/jimmunol.165.1.1"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4582\/1693748\/h82403004582.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4582\/1693748\/h82403004582.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T08:23:02Z","timestamp":1585124582000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/13\/4582\/17465\/Chimerism-and-cure-hematologic-and-pathologic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,15]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2003,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-03-0712","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,15]]}}}